IP Library Granted Patent US 8,470,783
Granted Patent B2
US 8,470,783 · App. 10/486,833 · Granted Jun 25, 2013

Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,470,783
App. No.
10/486,833
Granted
Jun 25, 2013
Kind
B2
Abstract

A therapeutic agent for prostate cancer and malignant lymphoma containing FK228 or a salt thereof as an active ingredient, and a method for evaluating an antitumor effect of a histone deacetylase inhibitor which includes at least a step of treating a test cell with a histone deacetylase inhibitor, a step of measuring change in the expression amount of a specific gene in the test cell before and, after the treatment with the inhibitor, comparing the both expression amounts.

Claims (3)

1. A method for treating prostate cancer, which comprises administering an effective amount of a compound represented by the formula (I)

or a salt thereof to a patient in need thereof.

2. The method of claim 1 , wherein the compound represented by the formula (I) is a compound represented by the formula (II)

Assignments (2)
MERGER Recorded Dec 12, 2005
From: FUJISAWA PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 017073/0257 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2005
From: SASAKAWA, YUKA; NAOE, YOSHINORI
To: FUJISAWA PHARMACEUTICAL CO., LTD.
Reel/Frame 016736/0991 →